Background 
is low. MTX and SSZ are used as monotherapy and in combination 5 . Although their mechanism of action remains unclear, several reports suggest that these drugs may differ in their effects on circulating cytokines and cytokine production 6 .
Two studies using the combination of drugs used in this study 7 . In the first, a controlled open step-up study in 40 patients "resistant" to SSZ, the combination was significantly better than MTX alone. In the second 8 , the individual drugs were compared with the combination in a parallel design from the outset. A modest trend favoring the combination of SSZ and MTX was seen, with comparable results from the two individual drugs. Nausea was documented as an adverse event more often in the combination group.
In general, a combination of two drugs may result in effects that are: multiplicative if one drug promotes the action of the other, additive if both effects add to each other, or sub-addative if the two drugs act in competition. These theoretical interactions are often not well studied when using combinations of DMARDs in real daily practice. Since the combination of MTX and SSZ is frequently used in the therapy for RA and has been tested in several clinical trials, we chose these drugs for the present study.
As the significant number of persons are affected by RA and most of the cases diagnose at the latter part of the course of the disease and initiation of the treatment with DMARDs also start at the latter part of the course of the disease and as a result disease outcome become worse. This study, can draw a conclusion that the initiation of treatment with DMARDs in the early part of the disease will benefit the patients. Commonly the Physician start treatment of Rheumatoid arthritis with single DMARD and when the response is not adequate with single drug then add another one. This study aims to start two DMARDs in initial part of the disease and also to compare the outcome between the patients using two DMARDs and single DMARD by applying DAS 28 score.
Methods:
All cases of RA in patients from July 2010 to June 2012, who were admitted in Rangpur Medical College Hospital and Medicine Specialists Chamber, Rangpur were included in this 24-month 3 arm clinical trial. This study of three groups. Group-I got MTX, Group-II got SSZ & Group-III got MTX+SSZ.
Selection criteria for the patients consists of: Patients of Rheumatoid arthritis as diagnosed by ACR criteria, patients of rheumatoid arthritis in active stage as defined by disease activity score (das28) ³ 3.2, patients with RA not yet getting dmards, patients with RA not yet getting steroid, age of onset of symptoms at or above 17 years. Exclusion criteria are : known sulphonamide allergy, pre-existing pulmonary fibrosis, significant renal disease (creatinine> 150mmol/dl), liver disease (ALT>80IU/L), known or planned pregnancy.According to inclusion and exclusion criteria the study subjects were selected. Evaluation of the patients included thorough history taking, meticulous physical examination and relevant investigations. Tables and charts were then made to summarize the various data of interest. The trial was done with all GCD (Good Clinical Practice) criteria. Randomization was done with block and equal distribution was ensured. The clinical trial was acceptance by the institutional ethical review committee.
Statistical analysis:
All data generated was statistically analyzed using the computer based statistical package for the social science (SPSS) in 16.0 version of windows. Levels of significance were calculated at a confidence interval of 95% (P<0.05).
Comparison among the groups was done by using Chisquare test & Anova test. Comparison within the group at different follow up was done by using paired t-test. Intention to treat analysis and per protocol analysis was done to show efficacy. Within the group between baseline with follow up at 3 month all groups were statistically significant (p<0.05) in paired t-test.
Results:
Within the group between baseline with follow up at 6 month, all groups were statistically significant (p<0.05) in paired t-test.
Within the group between baseline with follow up at 12 month of the study, all groups were statistically significant (p<0.05) in paired t-test. Within the group between baseline with follow up at 3 months all groups were statistically significant (p<0.05) by paired t-test.
Within the group between baseline with follow up at 6 months, months all groups were statistically significant (p<0.05) by paired t-test.
Within the group between baseline with follow up at 12 month of the study, all groups were statistically significant (p<0.05) by paired t-test. The mean DAS 28 score difference among the groups, at 3 month follow up, 6 month follow up and 12 month follow up of the study were statistically significant (p<0.001) but baseline was not statistically significant (p>0.05) by ANOVA test.
Within the group between baseline with follow up at 3 month, statistically significant (p<0.05) difference was found in group III but no statistical significant (p>0.05) difference were found in group I and group II by paired t-test.
Within the group between baseline with follow up at 6 month, all groups were statistically significant (p<0.05) by paired t-test.
Within the group between baseline with follow up at 12 month of the study, all groups were statistically significant (p<0.05) by paired t-test. A total number of 30 consecutive patients having rheumatoid arthritis treated 10 patients with MTX alone versus 10 patients with SSZ and 10 patients with MTX+ SSZ combination in the Department of Medicine unit, Rangpur Medical College Hospital (RMCH), Rangpur and Medicine Specialist Chamber during the period of July 2010 to June 2012 were included in this study. Patients with rheumatoid arthritis were treated with MTX alone was considered as group I versus SSZ was considered as group II and MTX+ SSZ combination was group III and they were followed up up to the end of the study. The present study findings were discussed and compared with previously published relevant studies.
In this current study it was observed that the mean age was found 35.0±11.07 years in group I, 42.0±11.83 years in group II and 40.6±12.37 years in group III, which were not statistically significant (P>0.05) among three groups. Majority of the patients having rheumatoid arthritis were in 4th decade and above in all three groups. Similarly, Shashikumar et al. (2010) showed the mean age of their study patients were 48.24±11.44 years in group I and 49.33±11.38 years in group II. On the other hand, higher mean age in patients having rheumatoid arthritis, which were 50.9 years, 52.5 years and 48.9 years in group I, group II and group II respectively. Similarly, Barrera et al. (1995) showed mean age was 52.5±13.6 years in group I and 58.9±10.6 years in group II. They have stated that the higher age range maybe due to increased life expectancy in their study patients.
In this present study it was observed that male was found 50.0% in group I, 30.0% in group II and 40.0% in group III. Female was found 50.0%, 70.0% and 60.0% in group I, group II and group III respectively. The difference was not statistically significant (P>0.05) regarding the sex distribution among the three groups of the study patients. Male to female ratio was 1:1.5 in the whole study patients, which indicated that rheumatoid arthritis was more common in female subjects. This gender relationship is equivalent with other authors who also found similar findings, because as is well known that this disease encompasses more women than men ,where the authors showed 78.0%, 84.0% and 76.0% were female in group I, group II and group III respectively. The mean DAS 28 score status improved significantly (p<0.05) at all follow up among three groups. Within the group between baseline with follow up at 3 month, statistically significant (p<0.05) difference was found in group III but no statistical significant (p>0.05) difference were found in group I and group II by paired t-test. Within the group between baseline with follow up at 6 month, all groups were statistically significant (p<0.05) by paired t-test. Within the group between baseline with follow up at 12 month of the study, all groups were statistically significant (p<0.05) by paired t-test. The primary outcome was measured the mean change in DAS observed 10 . As can be expected, the mean DAS changes were lower in SSZ than in DMARD-naive patients. This is in accordance with current evidence that treatment should be initiated in the early stages of RA in order to reduce disease activity most effectively: to achieve and sustain clinical remission 11 .
Besides the efficacy evaluation, it was noticed that the safety profile of the combination group in our study seems acceptable without any synergistic effect. Minor side effects like, GI upsets was found 2(20.0%) in group I, 3(30.0%) in group II and 2(20.0%) in group III. Headache was not found in group I, 1(10.0%) in group II and 1(20.0%) in group III. The difference was not statistically significant (P>0.05) among the three groups in chi square test. Similar, findings were also documented 12 .
